Milestone Pharmaceuticals: Playing The Long Ball In Cardiovascular Treatment [Seeking Alpha]
Milestone Pharmaceuticals Inc. - Common Shares (MIST)
Last milestone pharmaceuticals inc. - common shares earnings: 3/6 07:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
The firm faced setbacks this year with FDA CMC concerns and shareholder dilution, but now has sufficient cash to reach approval and its $75 million royalty milestone. CARDAMYST could be the first at-home PSVT therapy, targeting a large, underserved market with its impressive efficacy and safety. While MIST is pre-revenue and highly speculative, approval could unlock significant upside; a promising Phase 3 Afib treatment is in the pipeline and represents an even larger revenue opportunity. Existing shareholders should maintain positions ahead of the FDA decision. narvo vexar/iStock via Getty Images Founded in 2003 and headquartered in Montreal, Milestone Pharmaceuticals Inc. ( NASDAQ: MIST ) is a tiny biotech outfit that has been pushing one pipeline treatment through to an advanced stage for two different (if related) cardiovascular indications: This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of MIST either through st
Show less
Read more
Impact Snapshot
Event Time:
MIST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MIST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MIST alerts
High impacting Milestone Pharmaceuticals Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
MIST
News
- Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects [Yahoo! Finance]Yahoo! Finance
- Milestone Pharmaceuticals (NASDAQ:MIST) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MIST&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">WallMarketBeat
- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Shares Could Be 44% Below Their Intrinsic Value Estimate [Yahoo! Finance]Yahoo! Finance
MIST
Earnings
- 11/12/25 - Beat
MIST
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/13/25 - Form SCHEDULE
- MIST's page on the SEC website